Calquence is under clinical development by AstraZeneca and currently in Phase II for Graft Versus Host Disease (GVHD).

TRX-103 is under development for the treatment of graft versus host disease (GvHD), Crohn’s disease and unspecified indication. The therapeutic candidate comprises of allogenic Treg-cells which are ...

New imaging technique able to identify early signs of graft-versus-host-disease in transplant patients. Read on!

The FDA approved several drugs in December for the treatment of diseases including pancreatic adenocarcinoma, lung cancer, ...

The allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy Ryoncil (remestemcel-L-rknd) has been approv ...

Mesoblast's FDA approval for remestemcel marks a milestone for MSC therapies, but limited cash reserves pose risks for US ...

While gene therapy has emerged as a promising alternative for treating beta-thalassemia, hematopoietic stem cell ...

Meanwhile, synthetic gel aids in recovery after spinal surgery; Pittsburgh researchers create helper robots for people with ALS; a study finds nerve stimulation is effective against ...

The Food and Drug Administration (FDA) has approved Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft vs host disease (SR-aGvHD) in pediatric patients 2 months of age ...

INR:6468. gta san 1 century-old miracle drug & 2 billion-dollar products & 4 blockbuster drugs: the future of antithrombotic drugs is still promising Strategies for the d ...

The basis of the issued patent stems from the pioneering basic and clinical research work in the use of topical DNase conducted by Sandeep Jain, M.D., BA Field Professor of Ophthalmology and Director ...

INR:8172. mobile app Roche releases new data from two-year study of risdiplam in infants, children and adults with SMA Shengde's diabetes drug candidate CS02 Phase II ...